MedPath

Clinical Evaluation of a Specific Enteral Diet for Diabetics

Not Applicable
Conditions
Hyperglycemia
Diabetics
Metabolic Syndrome
Registration Number
NCT01247714
Lead Sponsor
Vegenat, S.A.
Brief Summary

The hypothesis of the proposed trials is that the regular intake of a specific diet designed for enteral nutrition of type 2 diabetic patients results into a better nutritional status. Thus, the aim of the study is to scientifically evaluate the healthy effects of the administration of an enteral complete diet for diabetic patients (T-Diet plus Diabet).

Detailed Description

This new complete diet has been carefully formulated, and incorporates functional ingredients based on:

1. A good gastrointestinal and metabolic tolerance of the product.

2. Beneficial outcomes in the nutritional status.

3. A good control of the glycaemic response and the lipidic profile, allowing an improvement of metabolic syndrome and insulin resistance indicators and hunger-satiety regulation.

The experimental enteral product is a complete diet that includes, as carbohydrates, high-molecular maltodextrin, resistant maltodextrin, fructooligosaccharides and cellulose, and does not contain added fructose. Indeed, this product contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
43
Inclusion Criteria
  • Diabetic Subjects older than 55 years.
  • Male or female
  • Requirement of total enteral nutrition (TEN) during at least 3 months.
  • Under medical supervision.
  • Voluntary informed consent for participation.
Exclusion Criteria
  • Unstable clinical situation
  • Fatal illness
  • Patients treated with lipidic drugs
  • Refusal to participate in the study or being enrolled in other clinical trials.
  • Social or humanitarian reason

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Nutritional status and Glycaemia9 months

* Evaluation of the nutritional status of diabetic patients fed the T-Diet Plus Diabet NP in comparison with the reference and the control diet.

* Evaluation of glycaemia and glycosylated hemoglobin

Secondary Outcome Measures
NameTimeMethod
Biochemicals parameters measure9 months

* Confirmation of gastrointestinal tolerance of the product

* To assess changes in glycaemic response and lipidic profile in theses patients in relation with the diet, including parameters characteristic of metabolic syndrome, insulin resistace and hunger-satiety mechanism.

* To analyse changes of incretins and gastrointestinal peptides levels.

* To compare inflammatory and endothelial damage markers related with cardiovascular morbidity.

* Genotyping and gene expression analysis of genes related with diabetes and insulin resistance

Trial Locations

Locations (1)

Department of Biochemistry and Molecular Biology II. University of Granada

🇪🇸

Granada, Spain

Department of Biochemistry and Molecular Biology II. University of Granada
🇪🇸Granada, Spain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.